
Collegium Pharmaceutical (COLL) Stock Forecast & Price Target
Collegium Pharmaceutical (COLL) Analyst Ratings
Bulls say
Collegium Pharmaceutical is a diversified biopharmaceutical company with a positive outlook due to their strong expected earnings, potential for growth in the ADHD market, successful acquisitions for expansion, and the upcoming launch of AZSTARYS. With a focus on ADHD and a well-positioned pain franchise, the company is expected to experience strong growth. This positive outlook is reflected in their Buy rating and a price target of $45 based on predicted EBITDA in 2027.
Bears say
Collegium Pharmaceutical is a company with a strong track record of strategic M&A in the ADHD and pain markets. However, recent sales performance for key products like AZSTARYS and JORNAY PM have underperformed, posing a risk to earnings and the company's ability to execute its acquisition-based growth strategy. And while the company's financials and potential for expansion into CNS and rare diseases look promising, the lack of internal innovation and the potential for further revenue erosion from the Nucynta franchise are key concerns. As such, a cautious outlook on the stock is warranted.
This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Collegium Pharmaceutical (COLL) Analyst Forecast & Price Prediction
Start investing in Collegium Pharmaceutical (COLL)
Order type
Buy in
Order amount
Est. shares
0 shares